SEC Filings - Aerovate Therapeutics, Inc.

Filing date	Form	Description	View
June 17, 2021	S-1/A	Amended Registration statement for face-amount certificate companies	0001104659-21-082643.pdf 0001104659-21-082643.rtf 0001104659-21-082643.xls View HTML
June 24, 2021	S-1/A	Amended Registration statement for face-amount certificate companies	0001104659-21-084790.pdf 0001104659-21-084790.rtf 0001104659-21-084790.xls View HTML
June 25, 2021	S-1/A	Amended Registration statement for face-amount certificate companies	0001104659-21-085693.pdf 0001104659-21-085693.rtf 0001104659-21-085693.xls View HTML
June 9, 2021	S-1	Registration statement for face-amount certificate companies	0001104659-21-078871.pdf 0001104659-21-078871.rtf 0001104659-21-078871.xls View HTML
June 29, 2021	EFFECT	EFFECT	9999999995-21-002582.pdf 9999999995-21-002582.rtf 9999999995-21-002582.xls View HTML
August 23, 2022	EFFECT	EFFECT	9999999995-22-002475.pdf 9999999995-22-002475.rtf 9999999995-22-002475.xls View HTML
May 6, 2021	DRS	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	0001104659-21-062408.pdf 0001104659-21-062408.rtf 0001104659-21-062408.xls View HTML
April 29, 2022	DEFA14A	Additional proxy soliciting materials - definitive	0001493152-22-011602.pdf 0001493152-22-011602.rtf 0001493152-22-011602.xls View HTML
April 19, 2023	DEFA14A	Additional proxy soliciting materials - definitive	0001798749-23-000030.pdf 0001798749-23-000030.rtf View HTML
April 29, 2022	DEF 14A	Official notification to shareholders of matters to be brought to a vote ("Proxy")	0001493152-22-011599.pdf 0001493152-22-011599.rtf 0001493152-22-011599.xls View HTML

Data provided by Kaleidoscope.